Xenon Pharmaceuticals - XENE Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XENE shares.
View XENE analyst ratings or view top-rated stocks.

12 equities research analysts have issued 1-year target prices for Xenon Pharmaceuticals' shares. Their XENE share price forecasts range from $45.00 to $60.00. On average, they expect the company's share price to reach $50.78 in the next twelve months. This suggests a possible upside of 29.6% from the stock's current price.
View analysts price targets for XENE or view top-rated stocks among Wall Street analysts.

Xenon Pharmaceuticals' stock was trading at $39.43 at the start of the year. Since then, XENE stock has decreased by 0.6% and is now trading at $39.19.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our XENE earnings forecast.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.08. The biopharmaceutical company had revenue of $8.12 million for the quarter, compared to analyst estimates of $7.76 million. Xenon Pharmaceuticals had a negative net margin of 862.06% and a negative trailing twelve-month return on equity of 17.31%. During the same quarter last year, the company earned ($0.25) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI).

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Xenon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include DNB Asset Management AS (0.15%), SG Americas Securities LLC (0.06%), New York State Common Retirement Fund (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), ProShare Advisors LLC (0.01%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Christopher John Kenney, Frank A Holler, Gary Patou, James R Empfield, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends.

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XENE stock can currently be purchased for approximately $39.19.

Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $2.45 billion and generates $18.44 million in revenue each year. The biopharmaceutical company earns $-78,880,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis.

The company employs 149 workers across the globe.

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for the company is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450.